ORIC
NASDAQ HealthcareOric Pharmaceuticals, Inc. - Common Stock
Biotechnology
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
�� 市场数据
| 价格 | $10.75 |
|---|---|
| 成交量 | 1,747,599 |
| 市值 | 1.20B |
| 贝塔系数 | 1.360 |
| RSI（14日） | 43.6 |
| 200日均线 | $11.04 |
| 50日均线 | $11.33 |
| 52周最高 | $14.93 |
| 52周最低 | $4.52 |
| Forward P/E | -6.94 |
| Price / Book | 2.76 |
🎯 投资策略评分
ORIC 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (91/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 🎈 Over-Hyped (7/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ORIC in your text
粘贴任何文章、记录或帖子 — 工具将提取 ORIC 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.